Damora Therapeutics, Inc. Ordinary Shares (DMRA)
PHARMACEUTICAL PREPARATIONS
Damora Therapeutics, Inc. Ordinary Shares (DMRA) is listed on Nasdaq, where it has traded since October 29, 2020.
- Listed On
- Nasdaq
- Listed Since
- October 29, 2020
- Employees
- 7
- Market Cap
- $1.3B
About Damora Therapeutics, Inc. Ordinary Shares
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 95 institutions reported holding DMRA, with 64.4 million shares worth $1.7 billion in aggregate. The largest reported holder was FMR, with 9.2 million shares worth $240.1 million. Of the 5 largest holders listed below, 2 added shares and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 9,232,979 | $240M | Added 2.07% |
| Fairmount Funds Management | 8,713,000 | $227M | Unchanged |
| Avoro Capital Advisors | 3,783,000 | $98M | Unchanged |
| VR Adviser | 3,603,595 | $94M | Unchanged |
| BlackRock | 3,162,068 | $82M | Added 1321.56% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is DMRA?
Damora Therapeutics, Inc. Ordinary Shares (DMRA) is listed on Nasdaq, where it has traded since October 29, 2020.
Who are the largest institutional holders of DMRA?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of DMRA were FMR, Fairmount Funds Management and Avoro Capital Advisors.
How many institutions own DMRA?
95 institutions reported a position in DMRA for the quarter ended June 30, 2026, worth $1.7 billion in total.
Did institutions buy or sell DMRA last quarter?
Of the 5 largest reported holders, 2 added shares and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for DMRA.
Every reported institutional holder, plus insider and congressional trades in DMRA, on SentiSense.